GlassScriptPhysician profile
Matthew D Doxey
NPI 1619598448
$1,187.05
in general payments reported to CMS, 2019-2025
12 companies · $306 in 2025
The $306 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $816 · 2024: $65.06 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $704 · Food and Beverage: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $704.28 |
| Food and Beverage | $482.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Titan Surgical Group, LLC | $531.11 | 2023-2025 | |
| Arthrex, INC. | $278.08 | 2023 | |
| Smith+Nephew, INC. | $115.92 | 2023-2025 | Grafix Pl |
| Medline Industries LP | $46.19 | 2025 | |
| Organogenesis INC. | $38.68 | 2025 | Affinity |
| Biocomposites INC | $36.52 | 2025 | Stimulan |
| Treace Medical Concepts, INC. | $34.42 | 2025 | |
| Sumitomo Pharma America, INC. | $26.15 | 2025 | Gemtesa |
| Bioventus LLC | $25.68 | 2025 | Exogen Ultrasound Bone Healing System |
| Heron Therapeutics, INC. | $20.04 | 2024 | Zynrelef |
| Linvatec Corporation | $18.61 | 2023 | Linvatec Extremities |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.65 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Doxey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.